Recent Research Analysts’ Ratings Changes for Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (NASDAQ: REGN) recently received a number of ratings updates from brokerages and research firms:

• 1/22/2026 – Regeneron Pharmaceuticals had its price target raised by analysts at Evercore ISI from $750.00 to $875.00. They now have an “outperform” rating on the stock.
• 1/10/2026 – Regeneron Pharmaceuticals was upgraded by analysts at Wall Street Zen from a “hold” rating to a “buy” rating.
• 1/8/2026 – Regeneron Pharmaceuticals was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 1/8/2026 – Regeneron Pharmaceuticals had its price target raised by analysts at Truist Financial Corporation from $798.00 to $820.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Regeneron Pharmaceuticals was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “buy” rating. They now have a $860.00 price target on the stock, up previously from $627.00.
• 12/29/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/20/2025 – Regeneron Pharmaceuticals was downgraded by analysts at Wall Street Zen from a “buy” rating to a “hold” rating.
• 12/15/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/12/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Morgan Stanley from $767.00 to $768.00. They now have an “equal weight” rating on the stock.
• 12/10/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Wells Fargo & Company from $700.00 to $745.00. They now have an “equal weight” rating on the stock.
• 12/8/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.
• 12/4/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at Canaccord Genuity Group Inc. from $850.00 to $1,057.00. They now have a “buy” rating on the stock.
• 12/4/2025 – Regeneron Pharmaceuticals had its price target raised by analysts at BMO Capital Markets from $725.00 to $850.00. They now have an “outperform” rating on the stock.
• 12/3/2025 – Regeneron Pharmaceuticals was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $767.00 price target on the stock.
• 12/1/2025 – Regeneron Pharmaceuticals had its “hold (c)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The shares were sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the sale, the vice president owned 4,233 shares in the company, valued at $2,757,503.19. This trade represents a 9.24% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Bonnie L. Bassler sold 1,500 shares of Regeneron Pharmaceuticals stock in a transaction dated Wednesday, January 7th. The shares were sold at an average price of $800.00, for a total transaction of $1,200,000.00. Following the completion of the transaction, the director directly owned 1,703 shares of the company’s stock, valued at approximately $1,362,400. This trade represents a 46.83% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Corporate insiders own 7.02% of the company’s stock.

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.